scholarly journals BRAF Non-V600E Mutated Metastatic Colorectal Cancer in a Young Patient: Discussion from a Case Report

2019 ◽  
Vol 12 (2) ◽  
pp. 426-429
Author(s):  
Laure Moisset ◽  
Judith Raimbourg ◽  
Sandrine Hiret ◽  
Jonathan Dauve ◽  
Michèle Boisdron-Celle ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Case Report ◽  
Lymph Node ◽  
Metastatic Colorectal Cancer ◽  
Peritoneal Carcinomatosis ◽  
Young Patient ◽  
Clinical Features ◽  
Short Review ◽  
Tumor Control

We report the case of a 32-year-old man with a caecal adenocarcinoma with major lymph node extension and peritoneal carcinomatosis, presenting a BRAF-K601E mutation. A triplet (5FU plus oxaliplatin plus irinotecan) combination with bevacizumab achieved tumor control but the disease progressed immediately after cessation and the patient died 8 months after the diagnosis. A short review of BRAF non-V600E mutations shows that outcome and clinical features depend on the mutation.

scholarly journals Role of lymph node yield and lymph node ratio in predicting outcomes in non-metastatic colorectal cancer

BJS Open ◽  
2018 ◽  
Vol 3 (1) ◽  
pp. 95-105 ◽  
Author(s):  
C. H. A. Lee ◽  
S. Wilkins ◽  
K. Oliva ◽  
M. P. Staples ◽  
P. J. McMurrick
Keyword(s):  
Colorectal Cancer ◽  
Lymph Node ◽  
Metastatic Colorectal Cancer ◽  
Lymph Node Ratio ◽  
Lymph Node Yield ◽  
Node Ratio ◽  
Node Yield

scholarly journals The Role of Dynamic ctDNA Monitoring During Combination Therapies of BRAF V600E-Mutated Metastatic Colorectal Cancer: A Case Report

2020 ◽  
Vol Volume 13 ◽  
pp. 11849-11853
Author(s):  
Zhan Wang ◽  
Chen-Yang Ye ◽  
Wen-Li Zhou ◽  
Miao-Miao Wang ◽  
Wei-Ping Dai ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Case Report ◽  
Metastatic Colorectal Cancer ◽  
Braf V600e ◽  
Combination Therapies

scholarly journals Liver transplantation for metastatic colorectal cancer (case report)

2019 ◽  
Vol 23 (4) ◽  
pp. 54-67
Author(s):  
I. A. Porshennikov ◽  
A. V. Sokolov ◽  
E. E. Shchekina ◽  
A. Yu. Chubukov ◽  
T. A. Tretyakova ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Liver Transplantation ◽  
Metastatic Colorectal Cancer ◽  
Short Review ◽  
Cancer Case ◽  
Current State ◽  
Cancer Metastases ◽  
Colorectal Cancer Case ◽  
Unresectable Liver Metastases ◽  
Colorectal Cancer Metastases

Liver transplantation is currently controversial for colorectal cancer metastases and not recommended in clinical guidelines. We report the first Russian case of liver transplantation from cadaveric donor in a patient with multiple bilobar unresectable liver metastases of colon cancer. We observe no recurrences within 10 months on everolimus-based immunosuppression and adjuvant treatment. The current state of the problem and the place of liver transplantation in metastatic colorectal cancer treatment are discussed in a short review.

scholarly journals Fatal Type B Lactic Acidosis Associated With Metastatic Colorectal Cancer: A Case Report With Review of Literature, Pathogenesis, and Treatment

2018 ◽  
Vol 6 ◽  
pp. 232470961878810 ◽  
Author(s):  
Bharatsinh Gharia ◽  
Karan Seegobin ◽  
Hetavi Mahida ◽  
Marwan Shaikh ◽  
Trevanne Matthews Hew ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Case Report ◽  
Lactic Acidosis ◽  
Metastatic Colorectal Cancer ◽  
Review Of Literature ◽  
Type B

scholarly journals Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9)

2018 ◽  
Vol 36 (7) ◽  
pp. 674-681 ◽  
Author(s):  
Thomas Aparicio ◽  
Francois Ghiringhelli ◽  
Valérie Boige ◽  
Karine Le Malicot ◽  
Julien Taieb ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Disease Progression ◽  
Induction Chemotherapy ◽  
Controlled Trial ◽  
Performance Status ◽  
Multivariable Analysis ◽  
Phase Iii ◽  
Tumor Control ◽  
Primary Tumors

Purpose Conflicting results are reported for maintenance treatment with bevacizumab during chemotherapy-free intervals (CFI) in metastatic colorectal cancer after induction chemotherapy. Patients and Methods In this open-label, phase III, randomized controlled trial, we compared the tumor control duration (TCD) observed with bevacizumab maintenance and with no treatment (observation) during CFI subsequent to induction chemotherapy with 12 cycles of fluorouracil, leucovorin, and irinotecan plus bevacizumab. After disease progression, the induction regimen was repeated for eight cycles, followed by a new CFI. Results From March 2010 to July 2013, 491 patients were randomly assigned. Disease progression or death occurred during induction chemotherapy in 85 patients (17%); 261 patients (53%) had at least one reinduction, 107 (22%) had two reinductions, and 56 (11%) had three or more reinductions. The median TCD was 15 months in both groups; the median progression-free survival (PFS) from randomization was 9.2 and 8.9 months in the maintenance group and observation groups, respectively. The TCD observed in both groups was higher compared with the TCD hypotheses of the trial. The median overall survival (OS) was 21.7 and 22.0 months in the maintenance and observation groups, respectively. In the per-protocol population, defined as patients with at least one reinduction after the first progression, the median duration of the first CFI was 4.3 months in both arms; the median TCD was 17.8 and 23.3 months ( P = .339), the median PFS was 9.9 and 9.5 months, and the median OS was 27.6 and 28.5 months in the maintenance and observation groups, respectively. Multivariable analysis revealed that female gender, WHO performance status ≥ 2, and unresected primary tumors were associated with a shorter TCD. Conclusion Bevacizumab maintenance monotherapy did not improve TCD, CFI duration, PFS, or OS.

Clinical Evidence of Regorifenib in Metastatic Colorectal Cancer: A Case Report

2019 ◽  
Vol 12 (2) ◽  
pp. 513
Author(s):  
K. Sukanya Mathew ◽  
Anjana Thomas ◽  
P R Roshni ◽  
Akhila Sivadas ◽  
K Pavithran
Keyword(s):  
Colorectal Cancer ◽  
Case Report ◽  
Metastatic Colorectal Cancer ◽  
Clinical Evidence

Assessing real-world outcomes in metastatic colorectal cancer with KRASG12C mutation.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e16072-e16072
Author(s):  
Hui-Li Wong ◽  
Wanyuan Cui ◽  
Matthew Loft ◽  
Margaret Lee ◽  
Rachel Wong ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Clinical Features ◽  
Real World ◽  
Predictive Biomarker ◽  
Tumor Location ◽  
Prognostic Impact ◽  
Braf Mutations ◽  
Specific Targeting ◽  
Metastatic Sites

e16072 Background: The KRASG12C mutation is present in 3% of colorectal cancer and is of particular interest given the recent development of specific targeting drugs. Previous data suggest KRAS (all) mutations may impact prognosis. Here we assess the clinical features and outcomes of real world patients with KRASG12C mutant metastatic colorectal cancer (mCRC) to explore any clinicopathologic associations and prognostic impact. Methods: Patients diagnosed with mCRC between January 2011 and December 2018 were included in this prospective mCRC registry. Patients with BRAF mutations, unknown or unspecified KRAS variants were excluded. Clinicopathologic features, treatment and overall survival (OS) were compared for RAS wildtype (RASWT) and KRASG12C mutant patients, and between KRASG12C and other (RASother) mutations. Results: Of 1308 patients analysed, 674 (52%) were RASmut, of whom 56 (8.3%) were KRASG12C. More patients with KRASG12C were female compared to RASother and RASWT (Table). No differences were observed in primary tumor location, number of metastatic sites and distribution of metastases. The proportion of patients undergoing metastasectomy was similar between KRASG12C and RASother, and KRASG12C and RASWT. There was no difference in the proportion of patients receiving systemic therapy. RASWT patients received more lines of therapy. Median OS was similar between KRASG12C, RASother, and RASWT: 31.7 vs 29.2 vs 31.8 months respectively (P = 0.545). Conclusions: KRASG12C mutations were observed in 4.3% of mCRC patients and in 8.3% of RAS mutant cases. Patients with KRASG12C have comparable clinical features to RASWT or RASother mCRC. Treatment and survival were also similar between groups. KRASG12C does not appear to be prognostic, but may be an important predictive biomarker as promising targeted therapies continue to be developed. [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document